OPKO Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on January 3, 2017, covering events occurring on December 30, 2016. The filing addresses updates to clinical programs and the status of outstanding convertible debt.
Key Financial Metrics
- Debt: $31.9 million outstanding in 3.0% Convertible Senior Notes due 2033.
- Conversion Price: $7.07 per share.
- Conversion Trigger Threshold: $9.19 (130% of conversion price).
- Conversion Rate: 141.4827 shares of common stock per $1,000 principal amount of Notes, plus applicable additional shares.
- Liquidity and Cash Flow: The filing text does not provide specific values for revenue, profit, cash flow, or general liquidity metrics.
Material Changes and Events
- Clinical Update: On December 30, 2016, the Company issued a press release regarding updates to its hGH-CTP clinical programs.
- Debt Convertibility: The Company determined that the conversion right for its 3.0% Convertible Senior Notes remains active through March 31, 2017. This is because the closing price of the common stock exceeded $9.19 for at least 20 of 30 consecutive trading days during the quarter ended December 31, 2016.
- Historical Context: This conversion right has been triggered in every quarter from March 31, 2015, through December 31, 2016.
Outlook, Risks, and Management Commentary
The Company has elected to satisfy its conversion obligation in shares of common stock. The Notes may remain convertible beyond March 31, 2017, if specific conditions in the Indenture are met in future measurement periods. The filing does not contain forward-looking financial guidance or specific risk factors beyond the mechanics of the debt conversion.
Key Facts for Investor Verification
- Verify the current market price of OPKO Health common stock relative to the $9.19 conversion trigger threshold.
- Confirm the exact number of shares issued upon conversion of the $31.9 million in Notes, including any early conversion provisions.
- Review the attached press release (Exhibit 99.1) for specific details on the hGH-CTP clinical program updates.
- Monitor future trading days to determine if the conversion right extends beyond March 31, 2017.